268 related articles for article (PubMed ID: 16098955)
21. Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-methylenedioxymethamphetamine.
Broening HW; Bacon L; Slikker W
J Pharmacol Exp Ther; 1994 Oct; 271(1):285-93. PubMed ID: 7965726
[TBL] [Abstract][Full Text] [Related]
22. Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats.
Miller RT; Lau SS; Monks TJ
Chem Res Toxicol; 1996 Mar; 9(2):457-65. PubMed ID: 8839050
[TBL] [Abstract][Full Text] [Related]
23. Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin.
Gudelsky GA
J Neural Transm (Vienna); 1996; 103(12):1397-404. PubMed ID: 9029406
[TBL] [Abstract][Full Text] [Related]
24. Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.
Shioda K; Nisijima K; Yoshino T; Kuboshima K; Iwamura T; Yui K; Kato S
Neurotoxicology; 2008 Nov; 29(6):1030-6. PubMed ID: 18722468
[TBL] [Abstract][Full Text] [Related]
25. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.
Commins DL; Vosmer G; Virus RM; Woolverton WL; Schuster CR; Seiden LS
J Pharmacol Exp Ther; 1987 Apr; 241(1):338-45. PubMed ID: 2883295
[TBL] [Abstract][Full Text] [Related]
26. The effects of co-administration of 3,4-methylenedioxymethamphetamine ("ecstasy") or para-methoxyamphetamine and moclobemide at elevated ambient temperatures on striatal 5-HT, body temperature and behavior in rats.
Stanley N; Salem A; Irvine RJ
Neuroscience; 2007 Apr; 146(1):321-9. PubMed ID: 17306465
[TBL] [Abstract][Full Text] [Related]
27. MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats.
Clemens KJ; Cornish JL; Li KM; Hunt GE; McGregor IS
Neuropharmacology; 2005 Aug; 49(2):195-207. PubMed ID: 15993443
[TBL] [Abstract][Full Text] [Related]
28. Pre-treatment with 3,4-methylenedioxymethamphetamine (MDMA) causes long-lasting changes in 5-HT2A receptor-mediated glucose utilization in the rat brain.
Bull EJ; Porkess V; Rigby M; Hutson PH; Fone KC
J Psychopharmacol; 2006 Mar; 20(2):272-80. PubMed ID: 16510485
[TBL] [Abstract][Full Text] [Related]
29. MDMA-induced serotonergic neurotoxicity enhances aggressiveness in low- but not high-aggressive rats.
Wallinga AE; ten Voorde AM; de Boer SF; Koolhaas JM; Buwalda B
Eur J Pharmacol; 2009 Sep; 618(1-3):22-7. PubMed ID: 19616536
[TBL] [Abstract][Full Text] [Related]
30. On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats.
Goñi-Allo B; Puerta E; Mathúna BO; Hervias I; Lasheras B; de la Torre R; Aguirre N
Neuropharmacology; 2008 Apr; 54(5):885-900. PubMed ID: 18329670
[TBL] [Abstract][Full Text] [Related]
31. Protein kinase C inhibition differentially affects 3,4-methylenedioxymethamphetamine-induced dopamine release in the striatum and prefrontal cortex of the rat.
Nair SG; Gudelsky GA
Brain Res; 2004 Jul; 1013(2):168-73. PubMed ID: 15193525
[TBL] [Abstract][Full Text] [Related]
32. Short-term effects of 3,4-methylen-dioxy-metamphetamine (MDMA) on 5-HT(1A) receptors in the rat hippocampus.
Giannaccini G; Betti L; Pirone A; Palego L; Fabiani O; Fabbrini L; Mascia G; Giusti L; Macchia M; Giusiani M; Martini C; Lucacchini A
Neurochem Int; 2007 Dec; 51(8):496-506. PubMed ID: 17602794
[TBL] [Abstract][Full Text] [Related]
33. Gender differences in hyperthermia and regional 5-HT and 5-HIAA depletion in the brain following MDMA administration in rats.
Wallinga AE; Grahlmann C; Granneman RA; Koolhaas JM; Buwalda B
Brain Res; 2011 Jun; 1398():13-20. PubMed ID: 21620380
[TBL] [Abstract][Full Text] [Related]
34. Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines.
Burrows KB; Nixdorf WL; Yamamoto BK
J Pharmacol Exp Ther; 2000 Mar; 292(3):853-60. PubMed ID: 10688597
[TBL] [Abstract][Full Text] [Related]
35. Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug.
Camarasa J; Pubill D; Escubedo E
Brain Res; 2006 Sep; 1111(1):72-82. PubMed ID: 16889759
[TBL] [Abstract][Full Text] [Related]
36. MDMA treatment 6 months earlier attenuates the effects of CP-94,253, a 5-HT1B receptor agonist, on motor control but not sleep inhibition.
Gyongyosi N; Balogh B; Kirilly E; Kitka T; Kantor S; Bagdy G
Brain Res; 2008 Sep; 1231():34-46. PubMed ID: 18638459
[TBL] [Abstract][Full Text] [Related]
37. Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of L-5-hydroxytryptophan.
Wang X; Baumann MH; Dersch CM; Rothman RB
Neuroscience; 2007 Aug; 148(1):212-20. PubMed ID: 17629409
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic interactions between MDMA and concomitants in MDMA tablets on extracellular dopamine and serotonin in the rat brain.
Ikeda R; Igari Y; Fuchigami Y; Wada M; Kuroda N; Nakashima K
Eur J Pharmacol; 2011 Jun; 660(2-3):318-25. PubMed ID: 21497593
[TBL] [Abstract][Full Text] [Related]
39. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine.
Stone DM; Johnson M; Hanson GR; Gibb JW
J Pharmacol Exp Ther; 1988 Oct; 247(1):79-87. PubMed ID: 2902215
[TBL] [Abstract][Full Text] [Related]
40. Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain.
Baumann MH; Clark RD; Budzynski AG; Partilla JS; Blough BE; Rothman RB
Ann N Y Acad Sci; 2004 Oct; 1025():189-97. PubMed ID: 15542717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
